{ "schemaVersion": 2, "eyebrow": "Psychiatry", "title": "Schizoaffective Disorder", "summary": "Schizoaffective disorder requires longitudinal confirmation of psychosis outside major mood episodes, exclusion of substance and medical causes, acute safety management, and a treatment plan that addresses persistent psychosis, the bipolar or depressive course, adherence, and suicide risk.", "seoDescription": "Clinical approach to diagnosing and managing schizoaffective disorder, including longitudinal diagnostic distinctions, safety assessment, antipsychotic strategy, and follow-up.", "clinicalQuestion": "How should clinicians confirm schizoaffective disorder and select treatment for acute symptoms, relapse prevention, and suicide risk?", "specialty": "Psychiatry", "audience": "U.S. physicians and medical trainees", "tags": [ "schizoaffective disorder", "psychosis", "bipolar type", "depressive type", "antipsychotic treatment", "clozapine", "long-acting injectable antipsychotic" ], "keyTakeaways": [ "Do not assign schizoaffective disorder from a cross-sectional presentation: establish a longitudinal period of at least 2 weeks of delusions or hallucinations without a major mood episode and determine whether major mood episodes occupy most of the total illness duration.[6][7][8][14]", "Obtain collateral records and informant history because psychotic patients may provide an incomplete illness timeline; the diagnosis depends on timing of psychosis, mood syndromes, and functional decline rather than mood lability alone.[7][8]", "Treat acute dangerousness, severe behavioral disorganization, catatonia, inability to care for self, or high suicide risk at the appropriate emergency or inpatient level while diagnostic clarification proceeds.", "Use an antipsychotic as the pharmacologic foundation when psychosis is active or recurrent; avoid unnecessarily high doses and high-dose antipsychotic polypharmacy because extrapyramidal symptoms are associated with later tardive dyskinesia and cognitive impairment.[3]", "Consider clozapine for persistent psychosis despite adequate antipsychotic treatment or refractory suicidality; its antisuicidal benefit is best established in schizophrenia and schizoaffective disorder, and discontinuation is associated with increased suicidality.[19]", "Offer a long-acting injectable antipsychotic when recurrent relapse, hospitalization, or documented nonadherence makes continuous oral treatment unreliable; the post-discharge period is a particularly high-risk transition for disengagement.[13][21][22]" ], "sections": [ { "id": "acute-safety-and-setting", "eyebrow": "First encounter", "heading": "Stabilize before resolving the diagnostic label", "intro": "Manage immediate risk and reversible contributors in parallel with longitudinal diagnostic reconstruction.", "paragraphs": [ "Determine whether the patient has imminent suicide risk, violence risk, severe agitation, command hallucinations, catatonia, delirium, intoxication or withdrawal, inability to meet basic needs, or medication nonadherence after a recent discharge. These findings determine emergency containment, observation, involuntary evaluation when legally indicated, and inpatient versus outpatient setting; they should not be deferred until schizoaffective disorder is confirmed.", "Obtain a medication list, pharmacy fill history, toxicology history, collateral history, and prior psychiatric records at the initial assessment. Reconstruct the onset and duration of psychosis, manic episodes, major depressive episodes, hospitalizations, substance exposure, and intervals of euthymia. A longitudinal view is necessary because patients with psychosis may not provide an accurate history, and collateral information from multiple sources is specifically important for diagnostic classification.[7]", "Perform a targeted medical and neurologic assessment when onset is atypical, cognition fluctuates, consciousness is impaired, neurologic signs are present, or medication/substance exposure could explain psychosis. Diagnose a primary schizoaffective illness only after substance-induced and medical causes of psychosis and mood symptoms have been considered and excluded clinically.[7][14]" ], "bullets": [ "Document current hallucinations, delusions, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms; schizophrenia Criterion A requires at least two symptoms over a significant portion of 1 month, with at least one being delusions, hallucinations, or disorganized speech.[14]", "Document syndromic mood episodes rather than nonspecific irritability, affective reactivity, aggression, or brief behavioral outbursts; the latter do not establish the major mood episode requirement.[8]", "At every acute encounter, ask directly about suicidal ideation, intent, plan, prior attempts, access to lethal means, command hallucinations, and recent clozapine discontinuation when applicable.[19]" ], "subsections": [], "table": { "caption": "Immediate findings that change disposition and the first diagnostic actions", "columns": [ "Finding", "Immediate action", "Diagnostic implication" ], "rows": [ [ "Imminent self-harm, violence, command hallucinations, profound disorganization, or inability to care for self", "Emergency psychiatric assessment; use a secure setting and inpatient treatment when outpatient safety cannot be maintained.", "Do not delay stabilization for longitudinal diagnostic certainty." ], [ "Fluctuating attention or consciousness, acute neurologic findings, or suspected intoxication/withdrawal", "Conduct urgent medical evaluation and targeted substance/medication assessment.", "Consider delirium, neurologic illness, medication effect, or substance-induced psychosis before a primary psychotic disorder.[7][14]" ], [ "No reliable illness chronology", "Contact family or other informants and retrieve prior inpatient, outpatient, and pharmacy records.", "A longitudinal timeline is required to distinguish schizoaffective disorder from schizophrenia and mood disorders with psychotic features.[7][8]" ] ] } }, { "id": "longitudinal-diagnostic-branching", "eyebrow": "Diagnostic decision", "heading": "Use the psychosis–mood timeline to classify the illness", "intro": "The key discriminator is whether psychosis persists independently of a syndromic major mood episode.", "paragraphs": [ "Confirm an uninterrupted illness period during which a major mood episode occurs concurrently with schizophrenia Criterion A symptoms. For a depressive episode to satisfy the schizoaffective criterion, depressed mood must be present; a history of isolated neurovegetative symptoms, irritability, or emotional outbursts is insufficient.[14]", "Then identify a documented interval of at least 2 weeks of delusions or hallucinations in the absence of a major mood episode. Without this interval, favor bipolar disorder or major depressive disorder with psychotic features when psychosis is confined to mood episodes.[6][7][14]", "Estimate the proportion of the total illness occupied by syndromic mood episodes. Schizoaffective disorder requires major mood episodes for the majority of the illness duration; if mood syndromes are brief relative to the psychotic illness, schizophrenia is generally the more coherent longitudinal formulation.[8][14]", "Assign bipolar type only when the longitudinal course includes a manic episode; major depressive episodes may also occur. Assign depressive type when the illness includes only major depressive episodes and no manic episode.[6][14] Revisit the diagnosis after new collateral information, sustained observation, or a change in course because schizoaffective disorder has relatively low diagnostic reliability compared with other psychotic disorders.[8]" ], "bullets": [ "Build a dated timeline that separately marks psychotic symptoms, manic symptoms, major depressive symptoms, medication exposure, substance use, and functional baseline.", "Require syndromic duration and severity for mood episodes; do not count reactive mood shifts or conflict-triggered outbursts as evidence that mood episodes predominate.[8]", "Record periods of psychosis without prominent mood symptoms explicitly, including dates, symptom type, corroborating source, and treatment status." ], "subsections": [], "table": { "caption": "Longitudinal distinctions among psychotic and mood disorders", "columns": [ "Longitudinal pattern", "Preferred formulation", "Next clinical step" ], "rows": [ [ "Psychosis occurs only during manic or major depressive episodes", "Bipolar disorder or major depressive disorder with psychotic features rather than schizoaffective disorder.[6][7]", "Treat and monitor the underlying mood disorder; reassess if psychosis later persists outside syndromic mood episodes." ], [ "Schizophrenia Criterion A symptoms plus major mood episodes, with at least 2 weeks of delusions or hallucinations without a major mood episode; mood episodes occupy most of the illness", "Schizoaffective disorder.[6][8][14]", "Specify bipolar or depressive type and plan treatment around both psychotic and mood relapse domains." ], [ "Chronic psychosis with mood symptoms present for a minority of the illness", "Schizophrenia is more consistent with the longitudinal pattern.[8][14]", "Treat persistent psychosis and address clinically meaningful mood symptoms without forcing a schizoaffective label." ], [ "Psychosis temporally linked to substances, medications, delirium, or medical/neurologic illness", "Substance/medication-induced or medical psychosis until evidence supports a primary disorder.[7][14]", "Treat the underlying cause and reassess the psychiatric diagnosis after resolution." ] ] } }, { "id": "pharmacologic-treatment", "eyebrow": "Medication strategy", "heading": "Anchor treatment to persistent psychosis, then target the mood course", "intro": "Medication selection should follow the active syndrome, prior response, adverse-effect burden, adherence pattern, and suicide risk.", "paragraphs": [ "Use antipsychotic treatment as the core pharmacologic intervention for active psychosis and maintenance of psychotic symptom control. Continue the antipsychotic regimen that achieved remission when tolerated; maintenance at the dose used for remission has been associated with the lowest relapse rates in schizophrenia-spectrum hallucinations.[10] When changing agents, define the target symptom, prior adequate trials, adherence, and adverse effects before labeling nonresponse.", "Avoid reflexive high-dose antipsychotic combinations. High-dose approaches and antipsychotic polypharmacy increase extrapyramidal symptom burden, and extrapyramidal symptoms are associated with future tardive dyskinesia and cognitive impairment; use the minimum effective dose and regularly assess whether each antipsychotic remains necessary.[3]", "For bipolar type, assess whether mania, mixed features, or recurrent depressive episodes persist after antipsychotic treatment and choose mood-directed pharmacotherapy according to the documented bipolar course. Avoid antidepressant monotherapy in a bipolar-spectrum presentation because antidepressant treatment in bipolar depression remains controversial owing to potential hypomanic or manic switching.[1]", "For depressive type, first verify that the current syndrome is a major depressive episode rather than negative symptoms, demoralization, medication adverse effects, substance use, or an evolving mixed/manic state. If using antidepressant treatment, monitor for activation, new decreased need for sleep, increased goal-directed activity, irritability, or psychotic worsening, and revise the diagnosis and regimen if these emerge.[1]" ], "bullets": [ "At each medication visit, document positive psychotic symptoms, mood episode symptoms, sleep, suicidality, adherence, adverse effects, substance use, and functional change.", "Before declaring treatment resistance, verify adequate treatment exposure, adherence, ongoing substance use, diagnostic accuracy, and whether mood symptoms or psychosis are the primary residual target.", "Avoid assuming that one medication strategy addresses both poles of bipolar-type illness; reassess manic, depressive, and psychotic recurrence separately." ], "subsections": [ { "heading": "When to consider clozapine", "paragraphs": [ "Consider clozapine when psychosis remains refractory after adequate antipsychotic treatment or when suicidality remains severe and recurrent despite a comprehensive plan. A systematic review found that clozapine's superior antisuicide effect is well established in schizophrenia and schizoaffective disorder, whereas evidence for refractory suicidality in bipolar disorder is limited.[19]", "Do not stop clozapine abruptly without an urgent risk and continuity plan when avoidable: discontinuation has been associated with increased suicidality.[19] Coordinate required hematologic monitoring, adverse-effect surveillance, and medication access before discharge or transfer to reduce preventable interruption." ], "bullets": [ "Use clozapine within a structured monitoring system that can reliably obtain required blood testing and rapidly address missed doses or emerging adverse effects.", "If lithium is considered with clozapine, recognize published reports of seizures after lithium was added to clozapine; use deliberate risk-benefit assessment and close monitoring rather than routine co-prescribing.[20]" ] } ], "table": { "caption": "Medication decisions driven by the dominant clinical problem", "columns": [ "Clinical problem", "Medication strategy", "Key tradeoff or monitoring focus" ], "rows": [ [ "Persistent or recurrent psychosis", "Use an antipsychotic and continue an effective remission regimen when tolerated.[10]", "Track response, adherence, extrapyramidal symptoms, and need for ongoing dose intensity.[3]" ], [ "Bipolar-type course with manic or mixed relapse", "Add mood-directed treatment based on the documented bipolar course while maintaining psychosis control.", "Avoid antidepressant monotherapy; monitor for treatment-emergent hypomania or mania.[1]" ], [ "Treatment-refractory psychosis or refractory suicidality", "Evaluate candidacy for clozapine within a monitoring-capable treatment setting.[19]", "Protect continuity; clozapine discontinuation is associated with increased suicidality.[19]" ], [ "Recurrent nonadherence or post-discharge disengagement", "Discuss a long-acting injectable antipsychotic after considering prior response and patient preference.[13][21][22]", "Coordinate injection follow-up and outreach after discharge." ] ] } }, { "id": "adherence-relapse-and-recovery", "eyebrow": "Long-term care", "heading": "Prevent relapse through continuity, adherence support, and integrated care", "intro": "The treatment plan must remain effective after discharge, not only during acute symptom control.", "paragraphs": [ "Identify nonadherence before each relapse-prone transition by reviewing missed appointments, medication access, adverse effects, insight, housing instability, substance use, and support availability. The transition from inpatient to outpatient care carries high risk for nonadherence and premature dropout, and fragmented care can undermine reengagement.[13] Schedule the follow-up pathway before discharge, including a named prescriber, medication supply, crisis contact, and a process for missed visits.", "Discuss long-acting injectable antipsychotic treatment when oral adherence is unreliable, the patient has repeated decompensations related to missed medication, or follow-up history suggests that observable medication delivery would improve continuity. Evidence syntheses specifically evaluate long-acting injectables for maintenance treatment in schizoaffective and bipolar disorders, and observational schizoaffective studies assess hospitalization outcomes with injectable treatment.[21][22]", "Use multidisciplinary care rather than medication-only follow-up when functional impairment persists. Comprehensive schizophrenia-spectrum care integrates antipsychotic pharmacotherapy with psychosocial interventions and supported employment; it should also include routine attention to co-prescribed psychotropics and adverse effects.[3] Coordinate psychiatric treatment with primary care to address metabolic, neurologic, substance-related, and social barriers that can destabilize the illness course." ], "bullets": [ "Make relapse planning concrete: identify early warning signs, who contacts the clinic, where urgent assessment occurs, and how medications will be continued during housing, insurance, or transportation disruptions.", "Review all psychotropics at each transition; anticholinergic and mood-stabilizing co-medications may signal high antipsychotic burden and merit reassessment.[3]", "Escalate outpatient intensity after hospitalization, missed injectable appointments, rapidly recurring mood episodes, emerging suicidality, or renewed substance use rather than waiting for florid psychosis." ], "subsections": [], "table": { "caption": "Follow-up priorities after acute stabilization", "columns": [ "Timepoint", "Required decision", "Action" ], "rows": [ [ "Before discharge", "Can medication delivery and follow-up be reliably maintained?", "Confirm medication access, next appointment, crisis plan, collateral contact, and a plan for missed doses or missed visits.[13]" ], [ "Early outpatient follow-up", "Is recurrence driven by residual psychosis, mood symptoms, adverse effects, or nonadherence?", "Measure each domain separately and adjust the regimen to the identified driver." ], [ "Repeated relapse or hospitalization", "Would observable treatment delivery reduce preventable interruption?", "Discuss long-acting injectable antipsychotic treatment and intensify coordinated outpatient supports.[21][22]" ], [ "Persistent suicidality or psychosis despite adequate treatment", "Is clozapine indicated and feasible?", "Arrange specialty-level clozapine evaluation with monitoring infrastructure and continuity planning.[19]" ] ] } } ], "faq": [ { "question": "Can schizoaffective disorder be diagnosed during a first psychotic hospitalization?", "answer": "Use a provisional longitudinal formulation when the necessary history is unavailable. Definitive classification requires evidence that delusions or hallucinations persisted for at least 2 weeks without a major mood episode and that major mood episodes occupied most of the illness course; collateral records are often necessary.[6][7][8][14]" }, { "question": "When should a long-acting injectable antipsychotic be discussed?", "answer": "Discuss it when recurrent nonadherence, missed appointments, relapse, or post-discharge disengagement makes oral continuity unreliable. Long-acting injectables have been evaluated for maintenance treatment in schizoaffective and bipolar disorders and for hospitalization outcomes in schizoaffective disorder.[13][21][22]" } ], "references": [ { "number": 1, "title": "Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project", "detail": "www.bmj.com", "url": "https://www.bmj.com/content/394/bmj-2026-100216", "authors": "www.bmj.com", "host": "www.bmj.com" }, { "number": 2, "title": "Treatment of schizoaffective disorder – a challenge for evidence ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0447.2009.01424.x", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 3, "title": "Real‐world comprehensive care of people living with schizophrenia: recommendations across different settings and clinical stages - Fusar‐Poli - 2026 - World Psychiatry - Wiley Online Library", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1002/wps.70066", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 4, "title": "Guideline for pharmacological treatment of schizophrenia 2022", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/npr2.12497", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 5, "title": "Bipolar II disorder: a state‐of‐the‐art review - Wiley Online Library", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/wps.21300", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 6, "title": "Schizoaffective Disorder - an overview", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/psychology/schizoaffective-disorder", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 7, "title": "Brief Psychotic Disorder - an overview | ScienceDirect Topics", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/brief-psychotic-disorder", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 8, "title": "Test-retest reliability of the diagnosis of schizoaffective disorder in childhood and adolescence – A systematic review and meta-analysis - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0165032717315859", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 9, "title": "Clozapine as a mood stabiliser for schizoaffective disorder", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0278584624001581", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 10, "title": "Treatment of Hallucinations in Schizophrenia Spectrum Disorders", "detail": "academic.oup.com", "url": "https://academic.oup.com/schizophreniabulletin/article/38/4/704/1869735", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 11, "title": "Digital Therapeutics for People with Schizophrenia Spectrum ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/schizophreniabulletin/article/52/4/sbaf134/8240860", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 12, "title": "Treatment of bipolar disorder: a systematic review of available data ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/ijnp/article/11/7/999/787005", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 13, "title": "[PDF] BUTLER HOSPITAL INSTITUTIONAL REVIEW BOARD PROTOCOL", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/50/NCT03955250/Prot_SAP_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov" }, { "number": 14, "title": "Schizoaffective Disorder - StatPearls - NCBI Bookshelf - NIH", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK541012", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 15, "title": "Early use of long‐acting injectable antipsychotics in bipolar disorder ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/bdi.13498", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 16, "title": "Concurrent Symposium Sessions - 2026 - Bipolar Disorders", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/bdi.70161", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 17, "title": "Efficacy and acceptability of pharmacological, psychosocial, and ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1002/wps.20881", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 18, "title": "What we know and what we don't know about the treatment of schizoaffective disorder - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0924977X1100040X", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 19, "title": "Prevention of suicide by clozapine in mental disorders: systematic review", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0924977X22009300", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 20, "title": "Combined clozapine-lithium treatment for schizophrenia and schizoaffective disorder - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0924933898800278", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 21, "title": "Long-acting injectable antipsychotics in the treatment of schizoaffective disorder: A retrospective mirror image study for hospitalizations and treatment costs - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1876201825002680", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 22, "title": "Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0924977X19301609", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 23, "title": "Bipolar pharmacotherapy and suicidal behavior: Part 3: Impact of antipsychotics - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0165032707002108", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 24, "title": "Impact of long-acting injectable antipsychotics vs. oral medication on relapses of patients with psychosis and bipolar disorder - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0165178123006261", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project", "detail": "www.bmj.com", "url": "https://www.bmj.com/content/394/bmj-2026-100216", "authors": "www.bmj.com", "host": "www.bmj.com", "snippet": ". Switch to mania after acute antidepressant treatment for bipolar depression: a systematic review and network meta-analysis of randomised controlled trials. EClinicalMedicine 2025;87:103413.pmid:40823496.doi:10.1016/j.eclinm.2025.103413\n\nOpenUrlCrossRefPubMedGoogle Scholar\n\n132. ↵\n\n 1. Vieta", "score": 0.47066417 }, { "number": 2, "title": "Treatment of schizoaffective disorder – a challenge for evidence ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0447.2009.01424.x", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "The aim of the present article was to review treatment studies for schizoaffective disorder and draw conclusions for clinical decision making.", "score": 0.45507812 }, { "number": 3, "title": "Real‐world comprehensive care of people living with schizophrenia: recommendations across different settings and clinical stages - Fusar‐Poli - 2026 - World Psychiatry - Wiley Online Library", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1002/wps.70066", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "10.4103/jopsys.jopsys\\_27\\_24Google Scholar\n 320Poletti M, Pelizza L, Preti A et al. Clinical high-risk for psychosis (CHR-P) circa 2024: synoptic analysis and synthesis of contemporary treatment guidelines. Asian J Psychiatr 2024; 100:104142.\n\n 10.1016/j.ajp.2024.104142PubMed Web of Science® Googl", "score": 0.4413124 }, { "number": 4, "title": "Guideline for pharmacological treatment of schizophrenia 2022", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/npr2.12497", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Combination of “atypical” antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder.", "score": 0.44059017 }, { "number": 5, "title": "Bipolar II disorder: a state‐of‐the‐art review - Wiley Online Library", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/wps.21300", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "This paper provides a comprehensive overview of the available research and current debate on the disorder, including its diagnostic criteria,", "score": 0.25404185 }, { "number": 6, "title": "Schizoaffective Disorder - an overview", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/psychology/schizoaffective-disorder", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Chapter\n\n## Schizophrenia/Psychosis\n\n2014, Encyclopedia of the Neurological Sciences (Second Edition)D. Rose\n\n### Schizoaffective Disorder\n\nSchizoaffective disorder represents prominent mood episodes in the context of chronic psychosis. It remains unclear if schizoaffective disorder represents a uni", "score": 0.680136 }, { "number": 7, "title": "Brief Psychotic Disorder - an overview | ScienceDirect Topics", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/brief-psychotic-disorder", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "#### Schizoaffective Disorder\n\nSchizoaffective disorder may only be diagnosed in individuals who have a documented history of a severe mood episode – depressive or manic. Thus, patients with schizoaffective disorder usually can be easily differentiated from those with schizophrenia because they will", "score": 0.55767727 }, { "number": 8, "title": "Test-retest reliability of the diagnosis of schizoaffective disorder in childhood and adolescence – A systematic review and meta-analysis - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0165032717315859", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "To meet the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, criteria for schizoaffective disorder, in addition to meeting the full criteria for schizophrenia, the patient must demonstrate evidence of a major mood episode for the majority of the duration of the illness.1 However, ", "score": 0.5533369 }, { "number": 9, "title": "Clozapine as a mood stabiliser for schizoaffective disorder", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0278584624001581", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "by M Peraire · 2024 · Cited by 4 — The diagnosis was confirmed through a semi-structured clinical interview to corroborate the category diagnosis according to the DSM-5 criteria.", "score": 0.5243709 }, { "number": 10, "title": "Treatment of Hallucinations in Schizophrenia Spectrum Disorders", "detail": "academic.oup.com", "url": "https://academic.oup.com/schizophreniabulletin/article/38/4/704/1869735", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "Current evidence thus suggests that continuous maintenance treatment with the initial dose used for symptom remission provides the lowest relapse rates. Depot", "score": 0.15583521 }, { "number": 11, "title": "Digital Therapeutics for People with Schizophrenia Spectrum ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/schizophreniabulletin/article/52/4/sbaf134/8240860", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "Clinical outcomes from the texting for relapse prevention (T4RP) in schizophrenia and schizoaffective disorder study . Psychiatry Res. 2020.", "score": 0.13662016 }, { "number": 12, "title": "Treatment of bipolar disorder: a systematic review of available data ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/ijnp/article/11/7/999/787005", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "One study reported that olanzapine was superior to lithium in the prophylaxis against manic and mixed episodes and with similar efficacy against depressive", "score": 0.12363014 }, { "number": 13, "title": "[PDF] BUTLER HOSPITAL INSTITUTIONAL REVIEW BOARD PROTOCOL", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/50/NCT03955250/Prot_SAP_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov", "snippet": "for clinical practice. Journal of Psychiatric Practice. 2009;15(1):34-44. 10. Dixon LB, Dickerson F, Bellack AS, et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophrenia Bull. 2010;36(1):48-70. 11. Nieuwlaat R, Wilczynski N, Navarro T, et al. In", "score": 0.3498664 }, { "number": 14, "title": "Schizoaffective Disorder - StatPearls - NCBI Bookshelf - NIH", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK541012", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Go to:\n\n## Pathophysiology\n\nThe exact pathophysiology of schizoaffective disorder is currently unknown. Some studies have shown that abnormalities in dopamine, norepinephrine, and serotonin may play a role.( white matter abnormalities in multiple areas of the brain, particularly the right lentiform ", "score": 0.6554468 }, { "number": 15, "title": "Early use of long‐acting injectable antipsychotics in bipolar disorder ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/bdi.13498", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Long-acting injectable antipsychotics (LAIs) are not routinely offered to patients living with bipolar disorder type I (BP-I),", "score": 0.18281944 }, { "number": 16, "title": "Concurrent Symposium Sessions - 2026 - Bipolar Disorders", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/bdi.70161", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Results: Across trials, mindfulness-based cognitive therapy and related interventions demonstrate small to moderate effects on depressive", "score": 0.15972821 }, { "number": 17, "title": "Efficacy and acceptability of pharmacological, psychosocial, and ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1002/wps.20881", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Top-tier evidence on the safety/tolerability of 80 medications in children/adolescents with mental disorders has recently been reviewed in", "score": 0.10542238 }, { "number": 18, "title": "What we know and what we don't know about the treatment of schizoaffective disorder - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0924977X1100040X", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "### Schizophr. Res.\n\n### The longitudinal polymorphism of bipolar I disorders and its theoretical implications\n\n### J. Affect. Disord.\n\n### Aripiprazole in schizophrenia and schizoaffective disorder: A review\n\n### Clin. Ther.\n\n### Double-blind, placebo-controlled comparison of the efficacy of sertra", "score": 0.31469303 }, { "number": 19, "title": "Prevention of suicide by clozapine in mental disorders: systematic review", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0924977X22009300", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Fifty-one studies were eligible for inclusion in the review. Most studies suggest a superior anti-suicide effect of clozapine in schizophrenia/schizoaffective disorder, compared to other antipsychotics, or no antipsychotic therapy, which is not due to the close monitoring of patients for blood dyscr", "score": 0.8116913 }, { "number": 20, "title": "Combined clozapine-lithium treatment for schizophrenia and schizoaffective disorder - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0924933898800278", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Combined clozapine-lithium treatment for schizophrenia and schizoaffective disorder - ScienceDirect\n## European Psychiatry. # Short communication Combined clozapine-lithium treatment for schizophrenia and schizoaffective disorder. ## Access through your organization. Check access to the full ", "score": 0.7065353 }, { "number": 21, "title": "Long-acting injectable antipsychotics in the treatment of schizoaffective disorder: A retrospective mirror image study for hospitalizations and treatment costs - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1876201825002680", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "### J. Affect. Disord.\n\n### A 10-year mirror-image study of effectiveness and cost of long-acting paliperidone palmitate injectable in patients with schizophrenia or schizoaffective disorder\n\n### Psychiatry Res\n\n### What we know and what we don’t know about the treatment of schizoaffective disorder\n", "score": 0.69399214 }, { "number": 22, "title": "Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0924977X19301609", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "### Assessment and management of bipolar disorder: summary of updated NICE guidance\n\n### B.M.J.\n\n## Cited by (100)\n\n### Real-world effectiveness of pharmacological treatments for bipolar disorder: register-based national cohort study\n\n### Long-acting injectable antipsychotics for the treatment of bi", "score": 0.6651719 }, { "number": 23, "title": "Bipolar pharmacotherapy and suicidal behavior: Part 3: Impact of antipsychotics - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0165032707002108", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Elsevier logo\nJournal of Affective Disorders\n\n## Journal of Affective Disorders\n\n## Published by: Elsevier\n\n### Published by\n\nElsevier\n\n# Research report Bipolar pharmacotherapy and suicidal behavior: Part 3: Impact of antipsychotics\n\n## Article preview\n\n## Abstract\n\n### Introduction\n\n### Methods\n\n#", "score": 0.6522641 }, { "number": 24, "title": "Impact of long-acting injectable antipsychotics vs. oral medication on relapses of patients with psychosis and bipolar disorder - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0165178123006261", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "### Eur. Neuropsychopharmacol.\n\n### Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis\n\n### Lancet\n\n### A randomized, double-blind, placebo-controlled tri", "score": 0.6490677 } ], "publishedAt": "2026-09-15T17:24:56.228620+00:00", "updatedAt": "2026-09-15T17:24:56.228620+00:00", "readingMinutes": 6, "slug": "schizoaffective-disorder" }